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1 Introduction 1 
Cervical cancer has the fourth highest incidence of cancers in women worldwide [1] and incidence is 2 
highest in low income countries, where routine cervical screening programmes are mainly absent 3 
and diets are deficient in possible protective factors [2]. It is well established that the main risk 4 
factor for cervical cancer is infection with the high-risk human papilloma virus (HR-HPV) [3] and for 5 
this reason HPV screening has been introduced into cervical screening programmes around the 6 
globe [201]. The human papilloma virus consists of many strains with HPV-16 and HPV-18 being 7 
responsible for around 70% of cervical cancers [202], however not all women with HR-HPV infection 8 
develop cervical cancer but the persistence of certain high risk strains is a risk factor for 9 
precancerous cervical cell lesions (CIN) and therefore increases the risk of progression to cervical 10 
cancer [3, 4, 5]. As women with cervical cell abnormalities and persistent infection with HR-HPV have 11 
an increased risk of developing cervical cancer [4], early detection of cervical cell abnormalities and 12 
of persistence of the virus are central to cancer prevention and mortality reduction. There is 13 
therefore, much interest in the factors that influence the acquisition and the persistence of HR-HPV 14 
infection as well as in the classification of the severity of early stage precancerous cell lesions, as an 15 
understanding of these processes will inform strategies to reduce cervical cancer risk. 16 
The mechanisms that support HPV persistence rather than clearance are not understood. HPV 17 
testing, while important in an assessment of cancer risk, does not predict whether the infection will 18 
be rapidly cleared or will persist. Monitoring for early stage cervical cell abnormalities requires 19 
scoring cell appearance by microscopy, which is time-consuming and has variable sensitivity. 20 
Changes that occur in the development of the cancer phenotype may include epigenetic 21 
modification to DNA, including methylation, and expression of genes important to the regulation of 22 
processes such as the cell cycle, DNA repair and apoptosis. Such changes in gene expression will be 23 
reflected in changes in both the cell proteome and metabolome and therefore, should be detectable 24 
by proteomic or metabolite profiling techniques.   25 
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Many metabolite profiling studies have concentrated on using Nuclear Magnetic Resonance, [6, 7] 26 
which is not practical as a routine technique in a clinical laboratory, or have concentrated on 27 
targeting specific metabolites [8] which involves a more complex analysis. Whilst targeting particular 28 
classes of compounds has value, such targeted analysis does not capture or provide a global picture 29 
of the most important discriminatory metabolites in the different cells. This means that some 30 
important metabolite changes and markers could easily be missed and therefore, particularly in the 31 
absence of specific hypotheses relating to mechanism underpinning HPV persistence, a non-targeted 32 
approach is more valuable.  33 
The current screening and triage for cervical cancer risk uses HR-HPV infection and cytology to 34 
inform patient treatment. The most vulnerable women are those in whom the HR-HPV infection is 35 
likely to persist but have a low grade cellular abnormality, as these women are generally not treated 36 
but recalled 12 months after the initial HPV test. Not only is there a high loss to follow-up among this 37 
group but there is potential for progression of low grade lesions.  For these reasons in this study we 38 
targeted HPV positive women with low grade lesions. 39 
The aim here is to present a rapid metabolite screening method using Direct Injection Mass 40 
Spectrometry (DIMS) along with Principal Component Analysis (PCA)as tools to discriminate between 41 
cervical cell samples at different early-stage precancerous change, and between those samples from 42 
which HR-HPV virus is cleared and those in which it persists. 43 
2 Materials and Methods 44 
2.1 Sample History 45 
The samples were provided by the Department of Oncology in the University of Sheffield Medical 46 
School. The samples were part of a wider study called the ARTISTIC trial (A Randomised Trial of HPV 47 
Testing in Primary Cervical Screening) [9] which involved routine cervical screening and HPV testing 48 
in 24,510 women aged between 20-64 years old. The primary aim of the ARTISTIC trial was to 49 
provide clear evidence on the costs, medical effects and psychosocial impact of adding HPV testing 50 
to cervical cytology screening. 51 
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At entry to the ARTISTIC trial cervical cell samples were collected from all women using liquid based 52 
cytology. All samples were examined for evidence of cervical cell abnormalities and HPV positivity 53 
and then stored at -80oC until further use.  54 
Usually the gold standard for new methods for cervical cancer screening and triage is histologically 55 
confirmed high grade dysplasia (CIN2+). Parameters for new methods include sensitivity, specificity, 56 
positive predictive values (PPV) and negative predictive values (NPV) for CIN2+ with ROC curves used 57 
to define cut-offs for the test. CIN2+ is a surrogate marker for cervical cancer and HPV persistence is 58 
a surrogate marker for CIN2+. However for the purpose of our investigation we used a classification 59 
of abnormality according to cytology investigations, and only women with a classification of normal, 60 
borderline/mild and >= moderate abnormality were recruited [10].  61 
For this study only the samples in the borderline and mild categories (with borderline being the least 62 
abnormal) were selected for analysis by metabolite profiling as these women would normally be 63 
recalled in 12 months’ time. Samples included those from women who tested HR-HPV positive at 24 64 
month follow up (cases), and women in whom no HR-HPV was detected at this point (controls). 65 
These samples were primarily selected for a study of epigenetic determinants of HR-HPV persistence 66 
[11] and surplus sample material was then used for the metabolite profiling described here.  67 
2.2 Sample Preparation 68 
160 samples were selected for metabolite analysis, based on the results of the cytology screen at 69 
baseline and HPV test at follow-up. All samples had a low-grade abnormality (borderline or mild) and 70 
tested positive for HR-HPV at baseline. Case samples were classed as women at baseline (the start of 71 
the trial) who were diagnosed with low-grade cervical neoplasia and who tested positive for HR-HPV 72 
infection and who were still HR-HPV positive 24 months later. Controls were women with the same 73 
diagnosis at baseline but who had cleared the infection and tested negative for HR-HPV 24 months 74 
later. In total there were 40 samples of each type which were selected at random: borderline case, 75 
borderline control, mild case and mild control.  76 
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HR-HPV classification was undertaken prior to this work by the ARTISTIC trial by using Hybrid 77 
Capture® 2 (hc2) according to the manufacturer’s instructions [10]. Positive results were expressed 78 
in relative light units (RLUs) compared with a positive control containing 1pgml-1 of HPV DNA. The 79 
high-risk HPV types detected by the assay are 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. 80 
Samples were classified as HPV positive according to the manufacturer’s instructions at the outset of 81 
the study, which was to use a positive cut off as 1 RLU/control. Persistence of HR-HPV was classified 82 
as the case samples which tested positive for the presence of HR-HPV at time 0 as well as at recall 24 83 
months later. 84 
The cell extracts for this study were prepared by authors HP and JF at the University of Sheffield 85 
Medical School [11] following the standard operating procedure for rapid purification of DNA from 86 
cell samples supplied with a standard QIAamp DNA Mini Kit, purchased from Qiagen (part number 87 
51304). The QIAamp DNA Mini Kit provides silica-membrane-based nucleic acid purification from 88 
tissues, swabs, CSF, blood, body fluids, or washed cells from urine use an optimised mix of buffers 89 
and enzymes. The supernatant which would normally be discarded after DNA extraction was 90 
retained and stored at -20°C, in this case, for the metabolite profile analysis.  91 
2.3 Direct Injection Mass Spectrometer Analysis 92 
All analysis was carried out by directly injecting each sample into a Waters Micromass Liquid 93 
Chromatograph Time of Flight mass spectrometer (LCT) (Waters, Manchester, UK). The mass 94 
spectrometer was operated in both positive and negative modes in order to analyse as many 95 
metabolites as possible, however only data from the positive mode analysis will be discussed here. 96 
The conditions for the analysis were capillary 3000V, extraction cone 5V, sample cone 15V, RF lens 97 
75V with source and desolvation temperatures at 100ºC and 150ºC respectively. Spectra were 98 
collected in continuum mode over the mass range 75-800amu at a rate of one scan per 0.5sec with 99 
an interscan delay of 0.1sec.  100 
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Due to the high concentration of buffer in the samples, matrix effects were minimised by diluting 101 
with 1:500 v/v with high purity water:methanol (50:50 v/v ) before analysis. This dilution was found 102 
to be optimal for sensitivity, reduced ion suppression effects and ease of analysis. 103 
The sample set of 160 samples, 40 of each of the 4 types, were arranged as a double blind 104 
experiment as the identity of the samples was unknown to the analyst, and the samples were all 105 
randomised for analysis. 106 
To show the robustness of this technique a small set of the samples were re-analysed in positive 107 
mode on a portable Advion CMS compact mass spectrometer. The conditions for this analysis were 108 
ESI voltage 3500V, capillary 180V, source voltage offset 20V, source voltage span 30V and capillary 109 
and source gas temperatures 250oC and 200oC respectively. Spectra were collected over the range 110 
50-800amu at a rate of one scan per 0.38sec with an interscan delay of 0.1msec. 111 
2.4 Data Processing and Multivariate Analysis 112 
Three replicate total ion chromatograms (TIC) of each individual sample were obtained to enable 113 
noise reduction according to the procedure defined by Overy and colleagues [12]. For each mass the 114 
summed intensity from the TIC was averaged to minimise variation and the data for each sample 115 
were normalised to the TIC for each biological replicate. In this case the data were rounded into 116 
0.4amu bins to minimise the number of peaks. The binned data sets were saved as metabolite 117 
profiles in text file format. 118 
The data were exported into SIMCA-P (Umetrics) to create PCA and OPLS-DA plots for the data 119 
analysis and the significantly changing bins were tabulated along with standard errors calculated 120 
from the standard deviation of the mean. 121 
3 Results and Discussion 122 
Direct injection mass spectrometry (DIMS) was used without any clean-up or chromatography step 123 
before analysis, for reasons of simplicity and speed. Each analysis took only 2 minutes using this 124 
approach and the samples required no preparation apart from a simple dilution. This made the 125 
procedure routine and with the current introduction of portable mass spectrometers the procedure 126 
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would be very quick and easy to run in a clinical laboratory, even for staff who are unskilled in mass 127 
spectrometry. The DNA extraction step removing large molecules could be further simplified. 128 
A challenge with this analysis was overcoming the problems of dealing with the difficult chemical 129 
matrix of the samples and possible suppression of ions due to the buffers used for the DNA 130 
extraction method. A large dilution had to be used (1:500) but this allowed the samples to be 131 
analysed routinely and did not significantly affect the sensitivity or the findings of the analysis as the 132 
overall number of peaks detected did not significantly change with increasing dilution. 133 
Initially all samples acquired in the same analysis mode were analysed together by PCA (data not 134 
shown). The case mild samples exhibited a clear cluster away from control mild but also away from 135 
borderline samples. Although mild cases and controls showed reasonably distinct clustering the 136 
borderline case samples did not show a tight cluster, rather they appeared to divide into two 137 
clusters. The mild and borderline samples were therefore plotted in separate PCA plots (figure 1). 138 
 139 
Fig. 1 PCA Scores Plot for mild samples only (a) and borderline sample only (b). The numbers refer to 140 
individual sample ID. Samples were analysed by direct injection mass spectrometry, mass intensities 141 
normalised to total ion count and the resulting data examined in a PCA analysis with SIMCA-P. 142 
The scores plot for the mild samples (figure 1a) shows a very clear difference between the case and 143 
control samples suggesting that the ability to clear the HPV infection is reflected in an altered 144 
metabolome.  145 
Analysis of the borderline samples separately (figure 1b) reveals that, although there is some 146 
clustering of cases as distinct from controls neither classification shows a tight cluster.  This contrasts 147 
with the clear clustering observed for the mild samples. The cytological classification of borderline 148 
which was used for the samples in the Artistic trial indicated that there was some level of 149 
abnormality but insufficient to classify the samples as mild. Therefore it is possible that this 150 
cytological classification of cellular abnormalities may not be particularly distinct and includes a high 151 
level of false positives [13, 14]. The division into two groups by metabolite profiling may reflect this 152 
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by distinguishing between those patients that clear the virus and those that do not and this different 153 
metabolite profile may not be associated with a low level of cell abnormality.  154 
From the loadings plot (figure 2) corresponding to scores plot for the mild samples (figure 1a) the 155 
metabolite bins 119, 155, 157 and 385.4 (seen in the right hand side of fig. 2) strongly influenced the 156 
separation of the classes, with the metabolite bin 385.4 having the strongest effect. At this stage the 157 
identification of the metabolites in the individual bins was not determined, as the aim of the study 158 
was to investigate whether the sample type contained a specific metabolite profile. The loadings 159 
plot for the borderline samples (figure not shown) shows that the 385.4 bin again strongly influences 160 
the separation seen in the scores plot. 161 
 162 
Fig. 2 Loadings plot to show mass bins responsible for separation in PCA scores plot (Fig. 1a) for mild 163 
samples in positive mode. The labels refer to individual mass unit bins. 164 
 165 
Further analysis of the data showed that although other bins were responsible for the separation in 166 
the PCA plot none was as striking, between cases and controls for both borderline and mild, as the 167 
385.4 bin. No identification of the metabolites present was undertaken in this study as it was 168 
intended to be a rapid screening method although identification could be done using MS-MS.   169 
 170 
 171 
The data collected from the analysis on the portable Advion CMS were treated in exactly the same 172 
way as the data collected from the Waters LCT and although the mass resolution and sensitivity of 173 
the two instruments is different the same clustering patterns were seen in the PCA scores plots 174 
(figure 3). The PCA loadings plots also showed the same patterns with the same major 385.4 mass 175 




Fig. 3 PCA scores plot generated from data collected by direct injection on an Advion portable 178 
compact mass spectrometer (CMS) for mild samples only in positive mode. Mass intensities 179 
normalised to total ion count and the resulting data examined in a PCA analysis with SIMCA-P. The 180 
numbers refer to individual sample ID. 181 
 182 
The findings are important because they suggest that metabolite profiling could offer an accurate, 183 
and time-effective tool for identifying women at increased risk of HPV persistence.Current screening 184 
for cervical cancer risk relies, as a first step, on a cytological assessment which can be difficult to 185 
classify at the low grade end of cervical cell abnormality and currently there is no screening tool for 186 
predicting HPV persistence. Metabolite profiling therefore has the potential to improve existing 187 
screening methods for cell abnormality and to supplement information about HPV positivity; the 188 
critically important risk factor for cervical cancer.  189 
Despite the differences in the likelihood of different HR-HPV types persisting, metabolite profiling 190 
was able to distinguish between cases and controls, suggesting that the metabolite profile was 191 
independent of strain of HPV and any changes in metabolism was due to the presence of the virus 192 
and not the individual type. The tool therefore would be useful even when HR-HPV type was not 193 
known or not factored into the analysis. 194 
Additionally, metabolite profiling was able to distinguish levels of low grade cell abnormality, which 195 
is difficult to do using conventional microscopic screening. This has the potential to reduce the risk 196 
of mis-classification thereby minimising the costly clinic recall for women providing a classification of 197 
‘indeterminate’. Metabolite profiles could also reveal new targets for pharmaceutical intervention 198 
for influencing HPV persistence [15, 16]. 199 
4 Concluding Remarks 200 
A mass spectrometer direct injection method for the analysis of a large number of biological 201 
replicates has been shown to be highly effective in discriminating samples on the basis of stage of 202 
low grade cervical cell abnormality, and also for HPV persistence. The ability to clearly predict HPV 203 
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persistence was greater for samples with a mild classification, which may reflect a more 204 
homogeneous sample than for those classified as borderline, which likely contain false positives. The 205 
ability to discriminate between women who need more intensive monitoring and those who do not 206 
could greatly benefit health care systems worldwide. Type of HPV strain was not taken into 207 
consideration for this study as it has been previously shown that type of strain has no effect on 208 
clearance of the virus [17]. Also age was not taken into consideration even though it is considered to 209 
be a factor influencing HR-HPV persistence because age was found not to be significantly different 210 
between cases and controls in the original study (30.1±8.9 vs 31.6±9.5years) [11]. With the increased 211 
portability of mass spectrometers and therefore the reduced cost this technique becomes more 212 
affordable for low and middle income countries. The method is fast, uses a very small amount of 213 
sample, and could readily be integrated into existing care protocols in different settings without any 214 
added complex sample preparation [18]. 215 
5 Future Perspectives 216 
Current screening and triage for cervical cancer risk rely on HR-HPV testing and a cytological 217 
assessment of cervical cell abnormality, which is difficult to classify at the low grade end of cervical 218 
cell abnormality. This is important because, given that there is no diagnostic tool for HR-HPV 219 
persistence, women with HR-HPV infection and low grade abnormality or normal cells, are generally 220 
not treated but recalled at a later date, with an associated loss to follow up. Metabolite profiling 221 
could become an integral part of screening and triage for cervical cancer risk, particularly in low and 222 
middle income countries, where significant progress is being made to introduce screening programs, 223 
involving low cost HPV testing and cytological examination. 224 
As the use of MS is increasing in clinical laboratories, due to improved knowledge, simplification of 225 
technology, changing perceptions and training, this novel and rapid method has real potential value 226 
for the prediction of HPV persistence and offers considerable efficiency savings in the prevention of 227 
this cancer type since patient recall could be targeted effectively to those most at risk. 228 




 Screening and diagnosis for cervical cancer requires time consuming and labour intensive 231 
cytology and in some countries also includes identification of the presence of high risk 232 
human papillomavirus (HR-HPV). With the advent of rapid metabolic profiling techniques 233 
and the introduction of portable mass spectrometers we examined whether cells 234 
distinguished by their cytology and the presence of a persistent HPV infection, could be 235 
easily differentiated by their metabolite profile. 236 
Experimental 237 
 Direct injection electrospray mass spectrometry (DIMS) was used for rapid metabolite 238 
profiling of cervical cell samples in a non-targeted double blind experiment.  239 
 Cell extracts were prepared using a routine DNA extraction procedure and the resulting 240 
supernatant, normally discarded, was analysed by mass spectrometry.  241 
 Data were interpreted using principal component analysis (PCA). 242 
Results and Discussion 243 
 The samples analysed had been collected from women infected with high risk human 244 
papillomavirus (HR-HPV) and diagnosed with one of two grades of cervical cytology and 245 
exhibiting either HPV persistence or clearance. 246 
 The metabolite profiles obtained clearly differentiated samples with different grades of cell 247 
abnormality and HPV persistence or clearance. 248 
Conclusion 249 
 The results indicate strongly that a simple metabolite extraction procedure and mass 250 
spectrometric profiling method could be used to rapidly identify women at increased risk of 251 
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